Annual report pursuant to Section 13 and 15(d)

Intangibles (Schedule of JMC Recognized Expense Related to its Product Licenses) (Details)

v3.22.1
Intangibles (Schedule of JMC Recognized Expense Related to its Product Licenses) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Beginning balance $ 14,629  
Ending balance 12,552 $ 14,629
Accutane [Member]    
Finite-Lived Intangible Assets [Line Items]    
Ending balance 3,939  
Anti-itch Product [Member]    
Finite-Lived Intangible Assets [Line Items]    
Amortization expense 0  
Journey [Member]    
Finite-Lived Intangible Assets [Line Items]    
Beginning balance 14,629 7,377
Amortization expense (2,474) (1,420)
Ending balance 12,552 14,629
Journey [Member] | Accutane [Member]    
Finite-Lived Intangible Assets [Line Items]    
Additions   4,727
Journey [Member] | Anti-itch Product [Member]    
Finite-Lived Intangible Assets [Line Items]    
Additions   $ 3,945
Journey [Member] | Exelderm [Member]    
Finite-Lived Intangible Assets [Line Items]    
Additions $ 397